Medical Devices: Page 33
-
Retrieved from Wikimedia Commons on December 15, 2021
UK shares roadmap for creation of new medtech regulatory framework
The MHRA plans to have the “core elements” of the new framework for medical devices in place by the next year.
By Nick Paul Taylor • Jan. 12, 2024 -
Resmed’s magnetized masks linked to 6 patient injuries, FDA says
The company contacted customers in November after determining magnets should be kept away from active implants and metallic medical devices.
By Nick Paul Taylor • Jan. 12, 2024 -
Explore the Trendlineâž”
Sitthiphong via Getty ImagesTrendlineMedical device industry continues to turn to AI
While the industry continues to embrace artificial intelligence, there are still questions about how the new technologies need to be regulated and if they are effective.
By MedTech Dive staff -
Intuitive CEO: Strong robot placements offset bariatric surgery slowdown
Speaking at the J.P. Morgan Healthcare Conference, CEO Gary Guthart said the robotics company is also seeing strong growth in general surgeries.
By Susan Kelly • Jan. 11, 2024 -
Masimo’s preliminary Q4 results, 2024 outlook exceed analyst expectations
Analysts see the update as evidence Masimo may be rebounding after failing to meet their expectations earlier in the year.
By Nick Paul Taylor • Jan. 11, 2024 -
Abbott CEO talks diabetes market, device pricing at J.P. Morgan conference
CEO Robert Ford is “very confident” in Abbott’s ability to pass $10 billion in sales of its Libre continuous glucose monitor products by 2028.
By Elise Reuter • Jan. 10, 2024 -
Livanova to close loss-making circulatory support business
Stifel analysts expressed support for the decision, predicting it will benefit revenue growth and profitability, and increase focus.
By Nick Paul Taylor • Jan. 10, 2024 -
GE Healthcare notice about ventilator formaldehyde risk triggers FDA alert
The company warned customers about elevated levels of the toxic gas when its EVair or EVair 03 optional compressors are used in certain conditions.
By Nick Paul Taylor • Jan. 10, 2024 -
Nevro laying off 63 people to strengthen financial position
The job cuts affect roles across corporate, sales and marketing, and operations.
By Nick Paul Taylor • Jan. 10, 2024 -
J&J’s Megadyne restricts use of electrodes over burn risk, triggering Class I FDA notice
The J&J unit limited the use of the product in children after receiving reports of burn injuries that could be particularly harmful to them.
By Nick Paul Taylor • Jan. 9, 2024 -
Medtronic focused on delivering durable revenue and profit growth
“Our top priority is restoring our earnings power, full stop,” CEO Geoff Martha said Monday at the J.P. Morgan Healthcare Conference.
By Susan Kelly • Jan. 9, 2024 -
Deep Dive
5 medtech trends to watch in 2024
From the M&A outlook and tough year-over-year comparisons to emerging markets like pulsed field ablation, here are the top medical technology trends to watch this year.
By Ricky Zipp • Jan. 9, 2024 -
Dexcom plans to launch new CGM this summer for people who don’t take insulin
The company also shared earnings expectations for 2024 at the J.P. Morgan Healthcare Conference.
By Elise Reuter • Jan. 9, 2024 -
Retrieved from Axonics on August 22, 2023
Boston Scientific to buy Axonics for $3.7B to gain incontinence treatment
The acquisition provides a high-growth addition to Boston Scientific’s urology business, analysts said.
By Susan Kelly • Jan. 8, 2024 -
US hospitals report increased procedure volumes, spending outlook in Q4 survey
Truist analysts wrote that Medtronic, Boston Scientific and Edwards Lifesciences could benefit from rising cardiology volumes, while Intuitive Surgical may benefit from improved capital spending.
By Nick Paul Taylor • Jan. 8, 2024 -
Nanowear gets FDA clearance for undergarment that estimates blood pressure
The company’s continuous blood pressure monitor allows clinical investigators to remotely capture data on patients.
By Nick Paul Taylor • Jan. 5, 2024 -
Thermo Fisher to lay off 74 California workers in restructuring
The scientific instruments maker, which has been streamlining operations to cut costs, said the latest job reductions would be effective Feb. 1.
By Susan Kelly • Jan. 5, 2024 -
Renovos secures FDA breakthrough status for bone graft alternative
When injected, Renovite acts as a scaffold for cells and helps localize and retain molecules that stimulate healing.
By Nick Paul Taylor • Jan. 5, 2024 -
FDA warns providers not to buy or implant Synovo’s total hip system
Last year, the FDA sent a warning letter to Synovo after finding that its femoral resurfacing cup had been “significantly changed or modified.”
By Nick Paul Taylor • Jan. 4, 2024 -
Apple Watch sales resume after latest twist in Masimo patent case
An appeals court has granted Apple’s emergency motion to pause the U.S. International Trade Commission’s ban on sales of its watches with a pulse oximetry feature.
By Susan Kelly • Jan. 3, 2024 -
Boston Scientific pulls forward expected approval for Farapulse PFA system
Analysts said a first quarter approval would increase their confidence in the company’s potential for sales growth of 10% or more.
By Nick Paul Taylor • Jan. 3, 2024 -
Roche to buy LumiraDx’s point-of-care technology for $295M
LumiraDx faces financial pressures amid declining test sales and a potential delisting from the Nasdaq.
By Elise Reuter • Jan. 2, 2024 -
Philips recalls MRI machines due to risk of explosion
The Food and Drug Administration labeled the recall as a Class I event. There has been one report of a machine exploding in the 22 years the system has been in use.
By Nick Paul Taylor • Dec. 22, 2023 -
Agilent to lay off about 400 workers amid site closures
Most of the reductions, which equal about 2% of the company’s global workforce, will be completed in the first quarter, Agilent said.
By Susan Kelly • Dec. 22, 2023 -
Resmed posts notice about risk of mask magnets interfering with medical implants
Like its rival Philips, Resmed has determined that patients should not wear magnetized masks near some implants.
By Nick Paul Taylor • Dec. 22, 2023 -
SEC charges former Stimwave CEO with $41M fraud scheme
The Securities and Exchange Commission alleges that Laura Tyler Perryman approved the creation of “fake” implantable parts for the company’s PNS device and defrauded investors of $41 million.
By Ricky Zipp • Dec. 21, 2023